KARYOPHARM THERAPEUTICS INC (KPTI) Stock News

USA - NASDAQ:KPTI - US48576U2050 - Common Stock

5.8 USD

-0.16 (-2.68%)

Last: 10/31/2025, 8:00:02 PM

6 USD

+0.2 (+3.45%)

After Hours: 10/31/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KPTI Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Benzinga

Karyopharm Therapeutics Earnings Preview

7 days ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

21 days ago - By: Benzinga - Mentions: KRC SLG PANW SHAK

This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

26 days ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

a month ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Zacks Investment Research - Mentions: VXRT

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

3 months ago - By: Zacks Investment Research - Mentions: COLL

Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates

3 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

3 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Zacks Investment Research - Mentions: ARDX

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

4 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Present at the Jefferies Global Healthcare Conference

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Zacks Investment Research

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

6 months ago - By: Zacks Investment Research

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

6 months ago - By: Zacks Investment Research - Mentions: OPTN

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

6 months ago - By: Zacks Investment Research - Mentions: NBIX

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)